The University of Southampton
University of Southampton Institutional Repository

Elexacaftor-Tezacaftor-Ivacaftor improves exercise capacity in adolescents with cystic fibrosis

Elexacaftor-Tezacaftor-Ivacaftor improves exercise capacity in adolescents with cystic fibrosis
Elexacaftor-Tezacaftor-Ivacaftor improves exercise capacity in adolescents with cystic fibrosis
Objective: Elexacaftor/Tezacaftor/Ivacaftor (Kaftrio®) is a cystic fibrosis transmembrane conductance regulator (CFTR) modulator with the potential to improve exercise capacity. This case-series of 3 adolescents with CF aimed to investigate whether 6 weeks treatment with Kaftrio® could improve exercise capacity in CFTR modulator naive adolescents with CF.

Methods: three adolescents (14.0 ± 1.4 years) with CF (FEV1% predicted: 62.5 ± 17.1; F508del/F508del genotype) completed an exhaustive maximal cardiopulmonary exercise test on a cycle ergometer to determine peak oxygen uptake (O2peak) and measure changes in gas exchange and ventilation during exercise at 6 weeks. We also analysed wrist-worn device-based physical activity (PA) data in 2 of the 3 cases. Validated acceleration thresholds were used to quantify time spent in each PA intensity category. 

Results: clinically meaningful improvements in O2peak were observed in all 3 cases (+17.6%, +52.4% and +32.9%, respectively), with improvements greatest in those with more severe lung disease and lower fitness at baseline. Although lung function increased in all cases, inconsistent changes in markers of ventilatory and peripheral muscle efficiency likely suggest different mechanisms of improvement in this case group of adolescents with CF. Device-based analysis of PA was variable, with one case increasing and one case decreasing. 

Conclusion: in this case-series we have observed, for the first time, improvements in exercise capacity following 6 weeks treatment with Kaftrio®. Improvements were greatest in the presence of more severe CF lung disease and lower aerobic fitness at baseline. The mechanism(s) responsible for these changes warrant further investigation in larger trials.
Elexacaftor-Tezacaftor-Iacaftor, cardiorespiratory fitness, CFTR modulator therapy, cystic fibrosis-transmembrane conductance regulator, peak oxygen uptake, respiratory disease
8755-6863
2652-2658
Causer, Adam J.
5a91c098-ffbd-4f66-841a-34a8ecae4e01
Shute, Janis K.
668c2b6d-d369-4536-8c78-7cf76f2e04c7
Cummings, Michael H.
49e830d1-aa87-4dd0-8258-35c3d5ac9c35
Shepherd, Anthony I.
7103ee4b-4fb4-41e0-8f00-9e647e15b3fb
Wallbanks, Samuel R.
153b083d-fb87-45ad-b571-517f738a2c6c
Pulsford, Richard M.
36d10809-075a-4358-b652-e9d25689b37d
Bright, Victoria
b9927700-00e1-489f-a671-27fa7d3d2995
Connett, Gary
55d5676c-90d8-46bf-a508-62eded276516
Saynor, Zoe L.
a4357c7d-db59-4fa5-b24f-58d2f7e74e39
Causer, Adam J.
5a91c098-ffbd-4f66-841a-34a8ecae4e01
Shute, Janis K.
668c2b6d-d369-4536-8c78-7cf76f2e04c7
Cummings, Michael H.
49e830d1-aa87-4dd0-8258-35c3d5ac9c35
Shepherd, Anthony I.
7103ee4b-4fb4-41e0-8f00-9e647e15b3fb
Wallbanks, Samuel R.
153b083d-fb87-45ad-b571-517f738a2c6c
Pulsford, Richard M.
36d10809-075a-4358-b652-e9d25689b37d
Bright, Victoria
b9927700-00e1-489f-a671-27fa7d3d2995
Connett, Gary
55d5676c-90d8-46bf-a508-62eded276516
Saynor, Zoe L.
a4357c7d-db59-4fa5-b24f-58d2f7e74e39

Causer, Adam J., Shute, Janis K., Cummings, Michael H., Shepherd, Anthony I., Wallbanks, Samuel R., Pulsford, Richard M., Bright, Victoria, Connett, Gary and Saynor, Zoe L. (2022) Elexacaftor-Tezacaftor-Ivacaftor improves exercise capacity in adolescents with cystic fibrosis. Pediatric Pulmonology, 57 (11), 2652-2658. (doi:10.1002/ppul.26078).

Record type: Article

Abstract

Objective: Elexacaftor/Tezacaftor/Ivacaftor (Kaftrio®) is a cystic fibrosis transmembrane conductance regulator (CFTR) modulator with the potential to improve exercise capacity. This case-series of 3 adolescents with CF aimed to investigate whether 6 weeks treatment with Kaftrio® could improve exercise capacity in CFTR modulator naive adolescents with CF.

Methods: three adolescents (14.0 ± 1.4 years) with CF (FEV1% predicted: 62.5 ± 17.1; F508del/F508del genotype) completed an exhaustive maximal cardiopulmonary exercise test on a cycle ergometer to determine peak oxygen uptake (O2peak) and measure changes in gas exchange and ventilation during exercise at 6 weeks. We also analysed wrist-worn device-based physical activity (PA) data in 2 of the 3 cases. Validated acceleration thresholds were used to quantify time spent in each PA intensity category. 

Results: clinically meaningful improvements in O2peak were observed in all 3 cases (+17.6%, +52.4% and +32.9%, respectively), with improvements greatest in those with more severe lung disease and lower fitness at baseline. Although lung function increased in all cases, inconsistent changes in markers of ventilatory and peripheral muscle efficiency likely suggest different mechanisms of improvement in this case group of adolescents with CF. Device-based analysis of PA was variable, with one case increasing and one case decreasing. 

Conclusion: in this case-series we have observed, for the first time, improvements in exercise capacity following 6 weeks treatment with Kaftrio®. Improvements were greatest in the presence of more severe CF lung disease and lower aerobic fitness at baseline. The mechanism(s) responsible for these changes warrant further investigation in larger trials.

Text
Pediatric Pulmonology - 2022 - Causer - Elexacaftor Tezacaftor Ivacaftor improves exercise capacity in adolescents with - Version of Record
Download (588kB)

More information

Accepted/In Press date: 25 June 2022
e-pub ahead of print date: 18 July 2022
Published date: 17 October 2022
Keywords: Elexacaftor-Tezacaftor-Iacaftor, cardiorespiratory fitness, CFTR modulator therapy, cystic fibrosis-transmembrane conductance regulator, peak oxygen uptake, respiratory disease

Identifiers

Local EPrints ID: 493829
URI: http://eprints.soton.ac.uk/id/eprint/493829
ISSN: 8755-6863
PURE UUID: 7ae6978c-056c-4feb-b467-df11c9a227f3
ORCID for Gary Connett: ORCID iD orcid.org/0000-0003-1310-3239
ORCID for Zoe L. Saynor: ORCID iD orcid.org/0000-0003-0674-8477

Catalogue record

Date deposited: 13 Sep 2024 16:50
Last modified: 14 Sep 2024 02:13

Export record

Altmetrics

Contributors

Author: Adam J. Causer
Author: Janis K. Shute
Author: Michael H. Cummings
Author: Anthony I. Shepherd
Author: Samuel R. Wallbanks
Author: Richard M. Pulsford
Author: Victoria Bright
Author: Gary Connett ORCID iD
Author: Zoe L. Saynor ORCID iD

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×